Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX301 plus temozolomide in glioblastoma (Phase IIa)
CTR20244225Phase 2Active
- Sponsor
- Hansi Bio
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of narazaciclib in glioblastoma (GBM), glioma, sponsored by Hansi Bio. Started Jan 2025; status: active.
02
Drugs
narazaciclib
03
Conditions
glioblastoma (GBM)glioma
Beyond the preview
Go deeper on CTR20244225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244225.